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Despite decades of successful use of cytotoxic
chemotherapy in acute myelogenous leukemia
(AML), the biological basis for its differential success
among individuals and for the existence of a thera-
peutic index has remained obscure. Rather than
taking a genetic approach favored by many, we
took a functional approach to ask how differential
mitochondrial readiness for apoptosis (‘‘priming’’)
might explain individual variation in clinical behavior.
We found that mitochondrial priming measured by
BH3 profiling was a determinant of initial response
to induction chemotherapy, relapse after remission,
and requirement for allogeneic bone marrow trans-
plantation. Differential priming between malignant
myeloblasts and normal hematopoietic stem cells
supports a mitochondrial basis to the therapeutic
index for chemotherapy. BH3 profiling identified
BCL-2 inhibition as a targeted strategy likely to
have a useful therapeutic index. BH3 profiling refines
predictive information provided by conventional
biomarkers currently in use and thus may itself
have utility as a clinical predictive biomarker.
INTRODUCTION
Though the majority of current cancer research has focused on
novel targeted therapies, empirically derived conventional
chemotherapy, largely targeting DNA and microtubules, has
cured millions of cancer patients over the last 5 decades. A
better understanding of why these therapies work can help us
more wisely utilize them presently and better exploit targeted
therapies in the future. Acute myeloid leukemia (AML) is a malig-
nancy primarily of adults in which a malignant myeloid clone in
the bone marrow is arrested in development and proliferates
abnormally. A highly successful empirically derived treatment
scheme combining cytarabine with an anthracycline has yielded344 Cell 151, 344–355, October 12, 2012 ª2012 Elsevier Inc.a 70% remission rate, greater overall survival, and even cures for
what is otherwise a fatal disease (Fernandez et al., 2009). The
only curative option for patients who are resistant to or relapse
after this induction regimen is allogeneic bone marrow or stem
cell transplantation (Allo-SCT), which consists of an intensive
preparatory chemotherapeutic regimen followed by introduction
of donor hematopoietic stem cells (HSCs) (Schlenk et al., 2008).
The success of the allogeneic approach is thought to depend on
an immunologic graft-versus-leukemia effect rather than direct
chemotherapeutic cytotoxicity for success.
The risk of induction-related death increases with age,
yet alternatives to high-dose chemotherapy have modest effi-
cacy (Appelbaum et al., 2006; Sekeres and Stone, 2002).
Patients at high risk of relapse after induction of a complete
remission are typically referred for allogeneic transplantation
because chemotherapy alone is usually insufficient to ensure
a durable remission in those cases (Schlenk et al., 2008).
However, due to treatment-related mortality and graft-versus-
host disease, allogeneic transplantation bears considerable
risks and should be used only for patients who are at high risk
of relapse with standard chemotherapy. Thus, predicting how
well a patient will respond to chemotherapy and the risk of
relapse is essential in deciding the best treatment course for
each individual patient. Currently, prognostic factors based on
cytogenetic abnormalities and gene mutations govern the use
of allogeneic transplantation (Do¨hner et al., 2010). Current strat-
egies in AML treatment are based on meticulous clinical obser-
vations rather than on a biological understanding of differential
response to standard chemotherapeutic regimens. We propose
here that the basis of differential response and clinical outcome
after chemotherapy in AML lies in the intrinsic mitochondrial
priming of the AML cells.
Mitochondrial priming is controlled by the BCL-2 family of
proteins (Brunelle and Letai, 2009; Brunelle et al., 2009; Certo
et al., 2006; Deng et al., 2007; Letai, 2008; Ni Chonghaile et al.,
2011; Ryan et al., 2010). This family consists of proapoptotic
and antiapoptotic members. If proapoptotic members over-
whelm the antiapoptotic members, the threshold of death is
crossed and the cell dies. The BCL-2 family consists of four
groups of proteins containing at least one of four homology
domains called the BH domains (BH1–BH4) (Brunelle and Letai,
2009; Danial and Korsmeyer, 2004). The first group consists of
proapoptotic multidomain ‘‘effector’’ members Bax and Bak.
Once activated, these proteins homo-oligomerize to induce
mitochondrial outer membrane permeabilization (MOMP) (Wei
et al., 2000; Wei et al., 2001), which results in the release of
cytochrome c (and other proapoptotic factors) from the mito-
chondria and loss of mitochondrial transmembrane potential
(Kluck et al., 1997). In the cytosol, cytochrome c cooperates in
the formation of amultimolecular apoptosome complex that initi-
ates a cascade of proteolysis executed by caspases (Zou et al.,
1999). Bim and Bid (and perhaps PUMA) proteins contain the
BH3 domain (‘‘BH3 only’’) and are proapoptotic ‘‘activators’’ of
Bax andBak (Gavathiotis et al., 2008;Wei et al., 2000). Antiapop-
totic members like BCL-2, BCL-XL, BCL-w, BFL-1, and MCL-1
contain multiple BH domains and can inhibit by sequestration
both the multidomain effectors and BH3-only activator proteins
(Certo et al., 2006; Cheng et al., 2001; Willis et al., 2005). The
last class consists of BH3-only proteins (Puma, Bmf, Bad,
Noxa, and Hrk) referred to as ‘‘sensitizers’’ because they lack
the ability to directly activate Bax/Bak (Certo et al., 2006; Letai
et al., 2002). However, they sensitize cells to death by antago-
nizing antiapoptotic members. Sensitizer proteins have unique
binding specificity to the antiapoptotic proteins and thus can
only inhibit certain antiapoptotic members (Certo et al., 2006;
Chen et al., 2005; Kuwana et al., 2005; Opferman et al., 2003).
Cellular stress caused by chemotherapeutic agents induces
the relative increase of BH3-only proteins. In cells highly primed
for death, this overwhelms antiapoptotic members and results in
cell death. In less primed cells, antiapoptotic reserves prevent
death.
We define priming functionally as the magnitude of response
of mitochondria to proapoptotic peptides derived from the
BH3 domains of BH3-only proteins (Deng et al., 2007; Ni Chong-
haile et al., 2011; Ryan et al., 2010). In practice, we measure this
as the release of cytochrome c or the loss of mitochondrial trans-
membrane potential caused by standardized doses of BH3
peptides in an assay we call BH3 profiling. The greater the loss
of mitochondrial transmembrane potential caused by the BH3-
only peptides, the more cells are primed for death. Loss of
potential caused by BH3 peptides like BIM that promiscuously
inhibits all the antiapoptotic members provides a measure of
overall priming (Ni Chonghaile et al., 2011). Sensitizer BH3
peptides like BAD, NOXA, and HRK inhibit only specific antia-
poptotic members and thus provide a measurement of depen-
dence on the antiapoptotic proteins they inhibit (Brunelle et al.,
2009; Certo et al., 2006). For instance, mitochondrial response
to the NOXA BH3 peptide is an indication of dependence on
MCL-1, whereas mitochondrial response to BAD BH3 peptide
is an indication of dependence on BCL-2, BCL-w, or BCL-XL.
Conventional chemotherapeutic agents generally kill via the
mitochondrial apoptotic pathway. We have previously found
that increased priming is the basis for differential clinical
response in several cancers, including multiple myeloma, acute
lymphocytic leukemia, ovarian cancer, and AML (Ni Chonghaile
et al., 2011). In the case of AML, we found that in a preliminary
series of 15 patients, achieving remission was related to the
degree of mitochondrial priming. Here, we expand upon thoseresults to explain a wide range of clinical phenomena associated
with AML that have previously lacked elucidation of a biological
mechanism. We find that differential priming determines not only
the initial response rate but also risk of relapse. Using AML cell
lines, we demonstrate that increasing mitochondrial priming
enhances chemosensitivity. We determine that the source of
a therapeutic index in AML depends upon AML cells being
more primed than normal hematopoietic stem cells (HSC). We
find that low priming identifies a subset of patients with a very
high risk of relapse for whom allogeneic stem cell transplantation
is likely required for cure. Finally, we use BH3 profiling to identify
dependence on BCL-2 present even in chemorefractory myelo-
blasts but not in normal HSC, suggesting another potential
avenue to rescue low-primed AML cases. Our results demon-
strate that the functional information about mitochondrial
apoptotic priming provided by BH3 profiling not only is useful
in defining biological mechanisms in AML but also can be poten-
tially exploited as a clinical predictive biomarker in AML.
RESULTS
Mitochondrial Priming Is a Major Determinant
of Topoisomerase II Inhibitor Efficacy
We first asked whether there was a relationship between
pretreatment mitochondrial priming and cellular response to
chemotherapeutic drugs used clinically in AML. To answer this
question, we BH3 profiled AML cell lines to determine their
priming (Figure 1A) and treated each line with the drugs. We
noted that one cell line, KG-1, had potent drug efflux activity
that was not inhibited by verapamil, so we excluded it from
further analysis (Figure S1A available online). We denote priming
as the percentage of mitochondrial charge loss caused by the
BIM BH3 peptide. We found that 0.3 mM of BIM BH3 peptide
gave the appropriate dynamic range to compare the priming of
the various AML lines (Figure 1A). Mitochondrial priming best
correlated with cellular response to the drugs etoposide, dauno-
rubicin, and mitoxantrone (Figures 1B–1H and S1D–S1F). It is
notable that these three drugs are all topoisomerase II inhibitors,
suggesting that reliance on mitochondrial priming for killing is
a property of this class of drugs (Nitiss, 2009). In contrast, araC
and clofarabine are nucleoside analogs, and azacitidine and
decitabine are hypomethylating agents, suggesting that killing
of AML cells by these classes of agents may be less reliant on
mitochondrial priming. Notably, proliferation rate, often cited
as a key determinant of chemotherapy response, did not corre-
late with chemosensitivity (Figures S1G–S1M). We tested
whether expression of individual BCL-2 family proteins corre-
lated with chemosensitivity. Of the seven tested, correlation
with BAX levels achieved statistical significance, though not if
a Bonferroni correction for multiple hypothesis testing were
applied (Figures S1H–S1N). Note that the correlation of BAX
with etoposide response is not as good as it is for BH3 profiling.
Finally, there is not a good correlation between BAX expression
and BH3 profiling (Figure S1O), suggesting that variability in BAX
expression alone cannot explain differences in priming. Overall,
these results suggest that monogenic predictors provide less
predictive information than the functional approach of BH3





Figure 1. Mitochondrial Priming Predicts Response to Topoisomerase II Inhibitors
(A–H) BH3 profiling response of each AML cell line to the BH3 peptides. Priming is measured by using 0.3 mM Bim response, the percent mitochondrial
depolarization induced by the Bim BH3 peptide. Priming is compared with killing by nucleoside analogs (A) araC and (B) clofarabine, topoisomerase II inhibitors
(D) daunorubicin, (E) etoposide, and (F)mitoxantrone, andDNA demethylating agents (G) azacytidine and (H) decitabine. All are one-tailed Spearman correlations.
Treatment with topoisomerase II inhibitors were done in the presence of 20 mM verapamil to exclude the effects of drug pumps.
See also Figure S1 and Table S1.Perturbation of Mitochondria Alters Chemosensitivity
of AML Cells
If priming truly causes as well as correlates with chemosensitiv-
ity, then increasing mitochondrial priming should increase
chemosensitivity. To test this, we lowered antiapoptotic BCL-2
expression in theMOLM13AML line by using shRNA knockdown
(Figure 2A). The MOLM13 BCL-2 partial knockdown produced
increased priming as measured by BH3 profiling (Figure 2B).
The increase in priming was associated with increased killing
by etoposide, daunorubicin, and mitoxantrone in proportion to
the quality of the knockdown (Figures 2C–2E).346 Cell 151, 344–355, October 12, 2012 ª2012 Elsevier Inc.In an alternative approach to directly altering mitochondrial
priming, we used the small molecule BCL-2 antagonist ABT-
737 (Oltersdorf et al., 2005). Only the two lines that are least
sensitive to the BAD BH3 peptide, OCI-AML2 and THP-1, could
be primed by ABT-737 without being killed by the inhibitor. As
expected, treatment of OCI-AML2 and THP-1 cell lines with
ABT-737 caused an increase in priming (Figures 2F and 2H),
and this increase in priming resulted in a concomitant increase
in chemosensitivity (Figures 2G and 2I). Thus, specific perturba-
tion of mitochondrial priming by two distinct methods resulted in






Figure 2. Specifically Increasing Mitochondrial Priming Increases Sensitivity to Chemotherapy
(A) BCL-2 protein levels after lentiviral introduction of shRNAs into the MOLM13 cell line.
(B) Priming as measured by depolarization induced by BIM BH3 at two concentrations.
(C–F and H) BCL-2 knockdown increased cellular sensitivity to (C) daunorubicin, (D) etoposide, and (E) mitoxantrone. Alternatively, priming was increased by
using the BCL-2 antagonist ABT-737 in the (F) THP-1 and (H) OCI-AML3 cell lines.
(G and I) Increased priming by ABT-737 also increased these cell lines’ sensitivity to etoposide, mitoxantrone, and daunorubicin. All data represent mean ± SD.thatmitochondrial priming is notmerely correlative but is actually
causative of chemosensitivity.
BH3 Profiling of Primary Blood and Bone Marrow
Samples
We next wanted to test whether priming was similarly determin-
istic in the clinical setting. We first needed to develop a reliable
method of BH3 profiling normal and malignant cells in heteroge-
neous patient blood and bone marrow samples. Often, only
a minority of nucleated cells in the bone marrow are AML myelo-
blasts. For this reason we adapted our BH3 profiling method to
identify cells of interest by FACS analysis (Lacombe et al.,
1997; Ni Chonghaile et al., 2011; Ryan et al., 2010) (Figure 3A).
We combined a patient AML sample with normal leukocytes toestablish the AML blast gate by using CD45 staining and side
scatter (Figure S2A). We validated that AML myeloblasts are
CD45lo and SSClo/mid by FACS sort followed by histological veri-
fication (Figure 3B). The digitonin used to permit peptide access
to mitochondria did not affect the gating of our AML blasts (Fig-
ure S2B). JC-1 dyewas used to detect mitochondrial charge loss
caused by BH3 peptides upon initiation of MOMP on the PE
channel (Cossarizza et al., 1993)(Figure S2C). Most patient
bone marrow and blood samples were available only as viably
frozen cells in 10% DMSO. We found that the freezing process
in 10% DMSO does not change the priming of the cells as long
as cell viability is high after thawing (Figure S2D). Moreover,
the same-patient sample frozen in two different media also
showed comparable priming readouts (Figure S2E).Cell 151, 344–355, October 12, 2012 ª2012 Elsevier Inc. 347
AB
Figure 3. BH3 Profiling by FACS Identifies AML Myeloblasts
(A) The FACS based BH3 profiling method for primary AML starts with Ficoll gradient purification of mononuclear cells from patient blood or bone marrow.
Mononuclear cells are stained with antibodies recognizing CD45, CD34, and CD38. Cells are then incubated in digitonin and peptide for 3 hr to allow the BH3
peptide time to inducemitochondrial depolarization. JC-1 dye is added tomeasure the remainingmitochondrial charge. AMLmyeloblasts are identified asCD45lo
and SSClo/mid. Mitochondrial depolarization induced by peptide was detected for the AML-gated cells and graphed.
(B) To validate our gating, a mixed patient sample was stained with CD45 and the AML, lymphocyte and monocyte populations were gated. These populations
were sorted and verified by histology.
See also Figure S2.Higher Pretreatment Mitochondrial Priming of Patient
AML Correlates with Clinical Induction Success
We used two different sources of clinically annotated AML
samples: Dana-Farber Cancer Institute and Memorial Sloan
Kettering. All samples were frozen prior to BH3 profiling. Investi-
gators performing BH3 profiling were blinded to clinical
response. In the primary test of our hypothesis that mitochon-
drial priming determines response to chemotherapy in AML,
the myeloblasts of patients who subsequently attained a
complete remission (CR) in response to induction therapy were
more primed than patients who did not achieve a CR (Figure 4A
and S3A). We considered induction therapies to be those that
included a topisomerase II inhibitor like daunorubicin, idarubicin,
mitoxantrone, or etoposide, essential components of most stan-
dard AML induction regimens.
In those patients where sufficient follow up was available, we
examined long-term duration of response, defined as 5 year
disease-free survival after completion of induction therapy (Fig-
ure 4B). Because we wanted to evaluate outcome after chemo-
therapy alone, we excluded patients who received an allogeneic
bone marrow or stem cell transplant after induction therapy. We
found that those who obtained a CR and were cured were more
primed than those that underwent a CR and then relapsed. The
latter were in turn more primed than those who did not achieve
CR. Thus, mitochondrial priming appears to determine both the
rateof clinical remissionaswell as itsduration.We foundnodiffer-
ence in proliferation rate in vivo of myeloblasts between patients
who attained CR and were cured and those of patients who did348 Cell 151, 344–355, October 12, 2012 ª2012 Elsevier Inc.not achieve CR (Figure S3C). This suggests that differences in
proliferation rate in vivo did not drive the differences in response.
If priming is a determinant of response, wewould expect to see
selection for decreased priming of AML cells after relapse. In our
cohort, we identified cases for which there was a CR followed by
a relapse. Of these, six cases were identified for which paired
samples were available, one obtained before treatment and
one after relapse (Figure 4C). We indeed observed in vivo selec-
tion for decreased mitochondrial priming in cases of relapsed
AML where the relapsed samples tended to be less primed
than the initial samples (p=0.031). As a control for timeor chemo-
therapy causing these changes in the absence of selection, we
examined myeloblast samples before and after chemotherapy
in patients who did not enter a complete remission, and found
no evidence of decreased priming. This suggests that in the
relapsed samples we are observing true selection rather than
a paradoxical direct chemotherapy effect because response is
required to observe the selection for decreased priming.
BH3 Profiling Further Refines Prognostic Information
from Cytogenetics and Genetics
Themostwidely used prognostic systemcurrently in use for AML
is that of the European LeukemiaNet (Do¨hner et al., 2010). This
classification system is based on classical cytogenetic results
as well as possession of a nucleophosmin (NPM1) or FLT-3
internal tandem duplication (ITD) mutation to classify patients
in one of four prognostic groups: favorable, intermediate I, inter-
mediate II, and poor. Although of demonstrated prognostic
A B C
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Figure 4. Relative Priming of AML Determines Clinical Outcome
(A) Preinduction priming asmeasured by Bim 0.1 mMdepolarization of patient AML samples comparedwith clinical response to induction therapy specified as CR
or no CR.
(B) Patients who achieve CR are separated into cured (no relapse and no transplantation) or relapse (relapse after initial CR). Highly primed patients having better
clinical outcome.
(C) Sequential samples were obtained from the same patients at two different dates. ‘‘Sensitive’’ patients initially obtained a CR and then relapsed. ‘‘Refractory’’
patients never achieved a CR and had a second biopsy taken after induction. Decrease in priming after relapse is statistically significant based on a one-tailed
Wilcoxon matched-pair signed rank test with a p value of 0.03. No such significant trend was observed for the refractory sequential samples.
(D–F) Patients were grouped based on their ELN relapse risk factors, and clinical outcome was compared with priming of primary AML samples. Patients with
normal cytogenetics lacking NPM1 and FLT3 information were classified as intermediate risk.
Significant differences were calculated by using a nominal one-tailed Mann-Whitney test. *p < 0.05, **p < 0.005, ***p < 0.0005. All data represent mean ± SD. See
also Figure S3 and Table S2.utility, the ELN criteria leave considerable dispersion in outcome
in each of the groups. Restricting our analysis to those patients
from 4A for whom we had cytogenetic data, we segregated
patients as favorable, intermediate (combining intermediate I
and II), or poor risk according to this system. As expected,
clinical outcome was best in the favorable group, worse in the
intermediate, and worst in the poor risk group. However, as ex-
pected, even within each of these groups, there was a mixture of
the clinical responses: CR (cured), CR (relapse), and no CR. We
asked whether BH3 profiling could better refine the prognostic
information provided by the ELN criteria, even within these
genetically defined groups. In each case it could. In the favorable
group, BH3 profiling could distinguish between CR (cured) and
CR (relapse) (Figure 4D). In the intermediate group, BH3 profiling
could distinguish between those destined for cure, relapse, or no
CR (Figure 4E). Finally, BH3 profiling could distinguish between
those destined to relapse and those who would be refractory
to initial therapy in the poor category (Figure 4F).
Cytogenetic abnormalities have long been demonstrated to
provide prognostic information about both short- and long-term clinical outcomes in AML (Mro´zek et al., 2004). However,
the important physiological effects of major chromosomal
alterations that confer altered prognosis and chemotherapy
response are obscure. We hypothesize that poor-risk cytoge-
netic abnormalities are related to low mitochondrial priming,
resulting in relative chemoresistance. Monosomy 7 is the one
cytogenetic abnormality present in sufficient abundance in our
sample for us to test this hypothesis. We therefore examined
the mitochondrial priming of myeloblasts containing monosomy
7 and found that they were significantly less primed than respon-
sive AML samples lacking monosomy 7 (Figure S3B). Low mito-
chondrial priming may provide for the first time a physiological
mechanism to connect this poor-risk cytogenetic finding to
poor chemotherapy response in AML.
Priming of Myeloblast Relative to Hematopoietic Stem
Cell Determines Therapeutic Index
If poorly primed AML is less sensitive to chemotherapy, what is
limiting oncologists from just giving higher doses of chemo-
therapy to the poorly primed population? In the clinic, drugCell 151, 344–355, October 12, 2012 ª2012 Elsevier Inc. 349
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Figure 5. Priming of AML Relative to HSC Priming Determines Clinical Outcome
(A) Theprimingof normalHSCs is comparedwithprimingof cured, relapse, andnoCRpatientsbyusingaone-tailedMann-Whitney test.Data representmean±SD.
(B) Kaplan-Meier survival curves based on pretreatment priming. Using the priming of normal HSCs as a cut-off, patients were categorized as high primed or low
primed. Patients with AML that are high primed have significantly better overall survival than low-primed patients.
(C) Priming of AML subsets based on CD34 andCD38 staining of patients who did not achieve a CR. Purple region represents the average and standard deviation
of normal HSC priming. All samples had a CD34+ progenitor population that was as primed or less primed than the HSCs.
**p < 0.005, ***p < 0.0005. See also Figure S4.dosing is limited by the tolerance of critical normal cells. Induc-
tion chemotherapy regimens for AML have evolved over the
past few decades based mainly on empiric observations of
what drugs were effective and what doses were tolerable. By
far, the most common dose limiting toxicity is bone marrow
toxicity. Because HSCs are responsible for regrowth of the
ablated bone marrow, we wondered whether the therapeutic
index of induction chemotherapy was dependent on the differ-
ence in chemosensitivity between normal HSCs and AML
myeloblasts.
We proceeded to test the hypothesis that the therapeutic
index of conventional induction chemotherapy in AML is based
on the relative mitochondrial priming of normal HSCs and AML
myeloblasts. That is, AML patients whose myeloblasts are less
primed than normal HSCs would have a lower rate of clinical
success, whereas those whose AML are more primed than
HSCs would have a higher rate of success. To test this, we
measured the priming of normal human HSCs with the method
used for our FACS BH3 profile of AML except that we identified
HSCs as LinCD34+CD38CD45RACD90+ (Majeti et al.,
2007)(Figure S4).
We indeed found that the priming of HSCs represents the
boundary between the priming ofmyeloblasts fromAMLpatients
cured by chemotherapy and those refractory to it (Figure 5A). We
therefore used the priming of HSCs as an index to categorize
AML cells into highly primed (more primed than HSCs) or low
primed (less primed than HSCs). In patients for whom we have
at least 3 years clinical follow up, we compared overall survival
based on whether the preinduction myeloblasts were more or
less primed than the mean of normal HSCs. Patients with highly
primedAMLachieve amuch greater overall survival than patients
with low-primed AML (Figure 5B). This finding supports the
concept that themitochondrial priming of HSCmay be important
in establishing themaximum tolerateddoses of induction therapy
and hence the therapeutic index of induction therapy in AML.
Myeloblasts can comprise a heterogeneous population as
demonstrated by differential expression of cell-surface antigens350 Cell 151, 344–355, October 12, 2012 ª2012 Elsevier Inc.CD34 and CD38 (Lapidot et al., 1994). We noted that some AML
cases that failed to achieve CR were relatively highly primed. We
examined the distribution of mitochondrial priming among
subpopulations based on CD34 andCD38 expression.We noted
that for all of these cases, the least mature CD34+ CD38 pop-
ulation was the least primed, often much less primed than more
mature populations (Figure 5C). This is particularly significant as
the CD34+CD38 subpopulation is thought to most commonly
harbor AML stem cells. Although it would take a much greater
sample to test this thoroughly, this raises the question of whether




When we examined the patients who attained long-term survival
after induction therapy without discriminating based on postin-
duction therapy, it became clear that some patients were
cured despite presenting with very poorly primed myeloblasts
(Figure 6A). To understand this observation, we examined
postinduction therapy. It became clear that all poorly primed
patients that were cured underwent allogeneic transplantation.
The biological significance of this finding is that it suggests
that apoptosis is irrelevant to the mechanism of graft-versus-
leukemia killing of myeloblasts in vivo in humans. Furthermore,
it suggests that given the otherwise poor prognosis of AML
patients presenting with poorly primed myeloblasts, allogeneic
bone marrow transplant may be required in this setting. To test
this, we compared the overall survival of low-primed AML
patients (myeloblasts less primed than the normal HSC mean)
according to whether or not they received an allogeneic trans-
plant (Figure 6B). The difference in survival is dramatic, with all
low-primed AML patients not receiving allogeneic transplant
dying in less than 18 months, whereas half of the transplanted
patients were alive at 5 years. In fact, the survival of the low-
priming patients receiving transplant was not significantly
different from that of the high-priming patients. Thus, although
A B Figure 6. Allogeneic Transplantation Bene-
fits Patients with Low Priming
(A) Comparison of priming of cured patients based
on postremission therapy. A one-tailed Mann-
Whitney test is used. Data represent mean ± SD.
(B) Kaplan-Meier Survival curves based on
priming and postremission therapy. Low-primed
patients who received a transplant had a better
overall survival than no-transplanted, low-primed
patients.
Log rank test, **p < 0.005.allogeneic transplant is not a guarantee of long-term survival in
patients presenting with poorly primed AML, it seems to be
a requirement thereof.
Chemosensitive and Chemoresistant Myeloblasts
Are More Sensitive To BCL-2 Antagonism
Than Normal HSCs
Although allogeneic bone marrow stem cell transplantation
apparently is an attractive option for low-primed chemoresistant
AML patients, its application is often limited by the age and
comorbidities of the patient, as well as the availability of a suit-
able allograft. We therefore asked whether BH3 profiling could
detect other differences between AML myeloblasts and HSCs
that would suggest alternative, less toxic therapeutic strategies
that could be exploited. Although we have so far focused on
priming measures based on the promiscuously interactive BIM
BH3 peptide, other BH3 peptides used in the BH3 profile inhibit
only specific antiapoptotic BCL-2 family proteins. Mitochondrial
dysfunction induced by such peptides is therefore a measure of
specific dependence on the antiapoptotic protein with which
they inhibit (Certo et al., 2006). For instance, we have previously
shown that MOMP induced by the BAD BH3 peptide indicates
dependence on BCL-2, BCL-XL, or BCL-w.
When we examined BH3 profiling results for our AML cell
lines, we found that all AML cell line mitochondria were more
sensitive to the BAD BH3 peptide than the NOXA BH3 (which
antagonizes MCL-1) or HRK BH3 (which antagonizes BCL-XL)
peptides (Figure 7A). This suggests a specific dependence on
BCL-2 or BCL-w for these cells’ survival. Prior work has indi-
cated that BCL-2 is the key protein (Konopleva et al., 2006). To
directly test whether this observed mitochondrial dependence
corresponded to a cellular dependence, we exposed the cell
lines to ABT-737, which antagonizes function of BCL-2, BCL-
w, and BCL-XL (Oltersdorf et al., 2005). We found that the mito-
chondrial response to the BAD BH3 peptide correlated well with
cellular killing by ABT-737 (Figures 7B and S5A). This result
demonstrates that BH3 profiling can detect antiapoptotic
dependencies that we can exploit pharmacologically to predict-
ably kill AML cells.
Next, we compared the response of mitochondria of primary
AML cells from both sensitive and refractory AML patients with
the response of HSCs to BAD, NOXA, and HRK BH3 peptides.
Most AML mitochondria from both refractory and sensitivepatients responded significantly more to the BAD BH3 peptide
than did that of the HSCs (Figure 7C). It is noteworthy that
increased mitochondrial sensitivity to BAD BH3 was also found
in the CD34+CD38 subpopulation of myeloblasts, the subpop-
ulation most commonly thought to harbor AML stem cells (Fig-
ure 7D). Taken in conjunction with an overall weak response
to the HRK BH3 peptide (Figure 7E), these results suggest
that AML cells, both bulk and CD34+CD38, regardless of
their clinical response to standard induction chemotherapy, are
usually more dependent on BCL-2 than are normal HSCs.
In contrast, mitochondria from HSCs were significantly more
sensitive to the NOXA BH3 peptide than were the majority of
the AML cells (Figure 7F). This suggests that normal human
HSCs are selectively more dependent on MCL-1 for survival
than are most AML cells. These results are congruent with the
demonstration of MCL-1 dependence of murine HSCs obtained
from mouse genetic models (Opferman et al., 2005). However,
this represents the first demonstration of MCL-1 dependence
in human HSCs. Note that BH3 profiling also identified a subset
of AML cases that were MCL-1 dependent, which could likely
benefit from MCL-1 directed therapy should such a drug
become available. This illustrates a strength of the BH3 profiling
tool, that it can provide important information about genetic
dependencies and the apoptotic pathway without requiring the
sort of genetic manipulation used in mice that is impossible in
primary human tissues.
Recall that all of the refractory AML patient cells were poorly
primed. Because most of these refractory cells are sensitive to
the BAD BH3 peptide, this suggests that BCL-2 inhibition might
benefit even refractory low-primed AML, offering a potential non-
transplant alternative to these poor prognosis patients. These
results prompted us to compare sensitivity of AML and HSCs
to treatment with ABT-737 (Figures 7G and S5B). As predicted
by the BH3 profiling results, primary AML cells, whether sensitive
or refractory to induction, were more sensitive to ABT-737 than
were normal HSCs. Two of the AML samples we tested were
poorly primed, chemorefractory AML cells (blue dots), both of
which were highly sensitive to ABT-737 killing. We also found
that cellular response to ABT-737 correlated with mitochondrial
sensitivity to the BAD BH3 peptide (Figure 7H). Interestingly,
cellular sensitivity to ABT-737 correlated inversely to mitochon-
drial dependency on MCL-1 as measured by the response to




Figure 7. BCL-2 Independence of HSCs Provides a Therapeutic Window for ABT-737
(A) BH3 profiling responses to BH3 peptides show BCL-2 dependency in all AML lines.
(B) Comparison of IC50 killing by ABT-737 with BAD peptide response for each line after 24 hr of treatment. Correlation determined by a one-tailed Spearman
correlation.
(C) Most AML cells from both sensitive and refractory patients are responsive to the BAD peptide, whereas HSCs are not.
(D) BAD peptide response of primary CD34+CD38 AML population is more pronounced than HSC response.
(E) HSCs and most primary AML are not responsive to the HRK peptide.
(F) HSCs are responsive to the NOXA peptide but most primary AML are not.
(G) Primary AML cells are significantly more sensitive to 1 mM ABT-737 than HSCs after 9 hr of treatment. Blue dots represent two low-primed AML refractory to
standard induction.
(H and I) Greater ABT-737 sensitivity correlates with greater BAD BH3 peptide sensitivity (H) and also correlates with less NOXA BH3 peptide sensitivity (I).
*p < 0.05, **p < 0.005, ***p < 0.0005; viability = annexin V-/PI- population. Data represent mean ± SD. See also Figure S5.MCL-1 can promote resistance to ABT-737 (Konopleva et al.,
2006; van Delft et al., 2006). Thus, BH3 profiling can detect resis-
tance as well as sensitivity to ABT-737. In summary, these
results suggest that there is a useful therapeutic index for
BCL-2 inhibition between malignant myeloblasts and normal
HSCs that can be exploited. Significantly, BCL-2 inhibition offers352 Cell 151, 344–355, October 12, 2012 ª2012 Elsevier Inc.a therapeutic index even in those patients who are poorly primed
and respond poorly to conventional chemotherapy. These
results suggest a promising therapeutic intervention for AML
patients with poor conventional options, and furthermore, BH3
profiling could provide a predictive biomarker of potential utility
in guiding BCL-2 directed therapy.
DISCUSSION
Over the past 4 decades, since effective chemotherapy regi-
mens for AML were introduced, several common observations
have dominated thinking about AML therapy. These observa-
tions include: (1)some cases have excellent responses to
chemotherapy, whereas others do not; (2) patients who relapse
after initial response are unlikely to be cured by chemotherapy
alone; (3) there is an unexplained therapeutic index for induction
chemotherapy; and (4)allogeneic transplant is required to rescue
relapsed and poor risk patients. Our results suggest that differ-
ences in pretreatment mitochondrial priming, as measured by
BH3 profiling, provide a biological explanation for these hereto-
fore unexplained clinical observations.
The observation that some patients achieve a complete remis-
sion andmaintain it after chemotherapy alone,whereasothers do
not achieve remission or relapse, has lacked a biological expla-
nation. Although cytogenetics have proven valuable as prog-
nostic indicators of this behavior, it should be noted that cytoge-
netics have behaved mainly as empirically derived markers, with
little power to explain the biological mechanism underlying differ-
ential killing of myeloblasts between patients. In this study, we
tested the hypothesis that the differentialmitochondrial tendency
to apoptosis, or priming, measured by BH3 profiling explains the
differential cellular and clinical response to cytotoxic chemo-
therapy. Our results support this hypothesis, as reflected in
both initial response (Figure 4A) and longer term freedom from
relapse (Figure 4B). This lends additional support to the concept
that mitochondrial priming is an important determinant of clinical
chemosensitivity that we supported in prior work in other
cancers, including multiple myeloma, acute lymphoblastic
leukemia, and ovarian cancer (Ni Chonghaile et al., 2011).
Another important observation is that patients who relapse
after an initial complete remission due to induction chemo-
therapy are unlikely to achieve long-term remissions from subse-
quent chemotherapy, no matter what combination of agents is
used. It is known that relapsed AML tends to be broadly more
chemoresistant than that of the initial presentation, but the
mechanism underlying this chemoresistance has been unclear.
Our results suggest that selection for reduced mitochondrial
priming in relapsed AML may well be an important determinant
of this chemoresistant phenotype (Figure 4C).
Success of induction chemotherapy depends on a therapeutic
index. That is, there must be a feature of myeloblasts that
renders them selectively more chemosensitive than critical
normal tissues. Perhaps surprisingly, given its centrality to the
treatment of AML, the biologic basis of this feature remains
poorly understood. There is no obvious AML-specific target ex-
ploited by standard induction chemotherapy, as it acts primarily
to damage DNA, a target present in normal as well as malignant
cells. We found that mitochondrial priming was a key determi-
nant of the therapeutic index between myeloblasts and normal
cells (Figure 5) and therefore one answer to the question, ‘‘why
does chemotherapy work’’?We could not identify a BCL-2 family
protein whose level replicated the performance of BH3 profiling,
supporting the concept that priming is likely the result of the
simultaneous contribution of many proteins, perhaps even
including some outside the BCL-2 family.Two important points go beyond the elucidation of biological
mechanisms of clinical behavior of AML and into potential
clinical application. The first is the identification of a therapeutic
index and a potential predictive biomarker for BCL-2 inhibition.
We have made the observation not only of myeloblast sensitivity
but also relative HSC insensitivity to BCL-2 inhibition. Others
have previously made a similar observation (Konopleva et al.,
2006). However, we demonstrated, based on our mitochondrial
BH3 profiling studies, that this is an on-target effect, based in
the mitochondrion, and further, that BH3 profiling is a potential
predictive biomarker. Significantly, we found that BCL-2 depen-
dence is observed even in cases where there was a poor
response to conventional induction chemotherapy, indicating
a potential strategy to rescue this difficult to treat population.
Notably, identifying this therapeutic index and validating
a predictive biomarker is of more than purely scientific interest
because clinical BCL-2 inhibition is now a practicable clinical
approach. Currently, Abbott Laboratories has two drugs in
clinical trials that directly target BCL-2, ABT-263, and ABT-199
(Roberts et al., 2012; Tse et al., 2008; Wilson et al., 2010). Both
are orally available counterparts of ABT-737. ABT-263causes
thrombocytopenia as an on-target toxicity due to its high-affinity
binding of BCL-XL, a protein required for platelet survival. This
toxicity may limit testing of ABT-263 in AML because patients
very commonly present with existing thrombocytopenia.
However, ABT-199 has greater selectivity for BCL-2 and lower
affinity for BCL-XL, so the chances are better for achieving in vivo
BCL-2 antagonism without exacerbating thrombocytopenia.
The second important advance is our identification of BH3
profiling as a potential predictive biomarker in AML, not only
for BCL-2 inhibition but also for conventional chemotherapy.
The understandable enthusiasm for BCL-2-targeted therapy
notwithstanding, we expect that conventional chemotherapy
and allogeneic bone marrow and stem cell transplantation,
with their demonstrated curative potential, will remain amainstay
of AML therapy for many years to come. Therefore, it is worth
considering how our findings could be used to better direct
use of these modalities. There are two important dilemmas often
encountered in the treatment of AML patients. In those under 60,
what is the best postremission strategy? In other words, who
should receive an Allo-SCT in first complete remission? Allo-
SCT has the potential to cure patients who are at high risk of
relapse, but it bears a higher treatment-related mortality and
can be accompanied by years of chronic graft-versus-host
disease. Therefore, the optimal strategy is to identify those that
are most likely to relapse after complete remission, and selec-
tively direct them to Allo-SCT. Currently, predictive tools such
as those used by the ELN employ a combination of genetic
and cytogenetic markers to perform such prediction. Although
useful, these still appear to be imprecise tools, and we have
found that BH3 profiling can actually improve the prognostic
capabilities of the conventional prognostic approach (Figures
4D–4F) and by itself identify a subpopulation that apparently
requires ALLO-SCT for cure (Figure 6).
Another decision-making dilemma faced by clinicians is
whether to administer high-dose induction chemotherapy to
newly diagnosed patients over 60 years of age. In older patients,
treatment-related mortality is higher and complete remissionCell 151, 344–355, October 12, 2012 ª2012 Elsevier Inc. 353
rates are lower. Clinical benefit appears to be restricted to those
who attain complete remission. Therefore, it would be useful to
be able to predict which patients are most likely to achieve
a complete remission and direct them to standard induction
chemotherapy, sparing those patients unlikely to achieve remis-
sion the significant side effects. BH3 profiling apparently can
identify those patients most likely to achieve a complete remis-
sion after induction chemotherapy (Figure 4). We will be testing
the predictive utility of BH3 profiling in these two clinical settings
in follow-up prospective clinical trials.
Our studies here do not directly demonstrate what upstream
factors determine the relative priming of different cells. It is likely
that activation of different oncogenes contributes because this
by itself can affect sensitivity to apoptosis. It is also likely that
differential activation of any of a number of tyrosine kinase-
driven pathways could affect priming because it is clear that
killing via inhibition of these pathways proceeds by perturbation
of BCL-2 family proteins and utilization of the mitochondrial
pathway of apoptosis. One strategy for improving response to
chemotherapy in poorly primed AML might be to selectively
increase priming in AML cells, perhaps with an agent that is
highly selective but less potent than conventional chemo-
therapy. Once the AML is primed into a range consistent with
good clinical response, then chemotherapy might be added.
We tested such a strategy in vitro and showed it to work by using
BCL-2 inhibition to prime AML cells and render themmore sensi-
tive to chemotherapy (Figures 2E–2H). We propose that such an
approach merits testing in clinical trials and that guidance by
BH3 profiling might assist with identifying useful priming agents.
There is considerable and appropriate interest in better
personalization of therapy in cancer patients, including in those
with AML. The vast majority of these personalization strategies
are based on genetics and are directed toward targeted thera-
pies. Even in these therapies, the gulf between genotype and
phenotype can be difficult to bridge. Here, we demonstrate
that BH3 profiling, an assay of mitochondrial apoptotic function,
can provide information that can potentially be exploited for
personalization of AML therapy in the application of BCL-2
antagonists, allogeneic bone marrow transplant, and conven-
tional chemotherapy.
EXPERIMENTAL PROCEDURES
Cell Lines and Drug Treatments
AML cell lines were grown in 20% fetal bovine serum (FBS) in standard RPMI
media for BH3 profiling and AML drug treatments. For details see Extended
Experimental Procedures.
BH3 Profiling of Cell Lines
Cell lines were profiled by using the plate-based JC-1 BH3 profiling assay
previously described (Ryan et al., 2010). Cells were permeabilized with digi-
tonin, exposed to BH3 peptides, and mitochondrial transmembrane potential
loss was monitored by using the ratiometric dye JC-1. For details see
Extended Experimental Procedures.
JC-1 FACS-Based BH3 Profiling of AML Primary Samples
Primary AML cells were obtained from the Leukemia Group and Pasquerrelo
Tissue Bank at the Dana-Farber Cancer Institute under institutional review
board (IRB)-approved protocol 01-206. Samples were also obtained from
through Dr. Mark Frattini at Memorial Sloan-Kettering Cancer Center under354 Cell 151, 344–355, October 12, 2012 ª2012 Elsevier Inc.IRB-approved protocols 95-091, 06-107, and 09-141. BH3 profiling was per-
formed as previously described (Ni Chonghaile et al., 2011). For details see
Extended Experimental Procedures.
Human HSC FACS
Normal human bone marrow was obtained from discarded deidentified bone
marrow filters used at the Dana-Farber Cancer Institute during bone marrow
isolation from healthy donors. Mononuclear cells were obtained by Ficoll.
Lineage depletion was done with Miltenyi’s Human Lineage Depletion Kit to
enrich for progenitor cells. The cells were further enriched with Miltenyi’s
CD34 Enrichment Kit. Cells were then stained with biotin-lineage cocktail
(Miltenyi), CD34-PECy7 (clone 8G12), CD38-V450 (clone HB7), CD90-APC
(clone 5E10), and CD45RA-biotin (clone HI100). Biotinylated cells were
detected by using streptavidin-APC-AlexaFluor750 (Invitrogen). The deple-
tion, enrichment, and antibody staining were all done in FACS buffer on ice.
Stained cells were BH3 profiled as described for primary AML. Human
HSCs were identified as cells in the LinCD34+CD38CD90+CD45RA
subpopulation (Majeti et al., 2007).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and two tables and can be found with this article online at http://dx.
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